In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS' Opdivo Blasts Through NICE

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) has won a recommendation from NICE, the health technology appraisal institute for England and Wales, for use on the NHS as a monotherapy for melanoma. The drug went straight to the final stages of the appraisal process and will compete against Merck & Co's own PD-1 inhibitor Keytruda (pembrolizumab). Meanwhile, research and patient organizations have expressed relief that NICE has okayed another "exciting" new immunotherapy for cancer.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts